Moderna Announces Data to be Presented at the 2025 International Congress of Inborn Errors of Metabolism
-
UEFA 'reluctantly' approves European league games in US, Australia
-
Hundreds protest in Madagascar as president to announce new premier
-
Greta Thunberg lands in Greece among Gaza flotilla activists deported from Israel
-
UNESCO board backs Egyptian ex-minister for top job: official
-
Facing confidence vote, EU chief calls for unity
-
Cash-strapped UNHCR shed 5,000 jobs this year
-
Mbappe to have 'small niggle' examined at France camp: Deschamps
-
Brazil's Lula asks Trump to remove tariffs in 'friendly' phone call
-
Paris stocks slide as French PM resigns, Tokyo soars
-
'Terrible' Zverev dumped out of Shanghai by France's Rinderknech
-
What are regulatory T-cells? Nobel-winning science explained
-
Indirect talks on ending Gaza war begin in Sharm El-Sheikh: Egypt media
-
OpenAI signs multi-billion dollar chip deal with AMD
-
Salah under fire as Liverpool star loses his spark
-
Paris stocks drop as French PM resigns, Tokyo soars
-
ICC finds Sudan militia chief guilty of crimes against humanity
-
Zverev dumped out of Shanghai Masters by France's Rinderknech
-
One hiker dead, hundreds rescued after heavy snowfall in China
-
Hundreds stage fresh anti-government protests in Madagascar
-
Feminist icon Gisele Pelicot back in court as man appeals rape conviction
-
US government shutdown enters second week
-
Kasatkina ends WTA season early after hitting 'breaking point'
-
Paris stocks drop as French PM resigns
-
Death toll from Indonesia school collapse rises to 63
-
Medicine Nobel to trio who identified immune system's 'security guards'
-
UN rights council launches probe into violations in Afghanistan
-
UK author Jilly Cooper dies aged 88
-
Jilly Cooper: Britain's queen of the 'bonkbuster' novel
-
Streaming stars' Le Mans race scores Twitch viewer record
-
England rugby star Moody 'shocked' by motor neurone disease diagnosis
-
Leopard captured after wandering into Indonesian hotel
-
Israel, Hamas due in Egypt for ceasefire talks
-
Rescuers scramble to deliver aid after deadly Nepal, India floods
-
Tokyo stocks soar on Takaichi win, Paris sinks as French PM resigns
-
OpenAI offers more copyright control for Sora 2 videos
-
Australia prosecutors appeal 'inadequate' sentence for mushroom murderer: media
-
Rugby World Cup-winning England star Moody has motor neurone disease
-
Trump says White House to host UFC fight on his 80th birthday
-
Vast reserves, but little to drink: Tajikistan's water struggles
-
US government shutdown may last weeks, analysts warn
-
Arsenal host Lyon to start new Women's Champions League format
-
Gloves off, Red run, vested interests: Singapore GP talking points
-
Bills, Eagles lose unbeaten records in day of upsets
-
Muller on target as Vancouver thrash San Jose to go joint top
-
Tokyo soars, yen sinks after Takaichi win on mixed day for Asia
-
China's chip challenge: the race to match US tech
-
UN rights council to decide on creating Afghanistan probe
-
Indonesia sense World Cup chance as Asian qualifying reaches climax
-
ICC to give war crimes verdict on Sudan militia chief
-
Matthieu Blazy to step out as Coco's heir in Chanel debut
NYSE - LSE
| RBGPF | -2.92% | 76 | $ | |
| CMSC | -0.38% | 23.78 | $ | |
| GSK | 0.17% | 43.425 | $ | |
| RIO | 1.5% | 67.115 | $ | |
| NGG | 0.47% | 73.78 | $ | |
| RYCEF | -0.57% | 15.67 | $ | |
| SCS | -0.74% | 16.985 | $ | |
| CMSD | -0.2% | 24.4 | $ | |
| VOD | -0.8% | 11.27 | $ | |
| JRI | -0.56% | 14.22 | $ | |
| RELX | 0.61% | 46.695 | $ | |
| BCC | -3.01% | 75.36 | $ | |
| AZN | 0.11% | 85.4 | $ | |
| BTI | -0.34% | 51.065 | $ | |
| BCE | -0.73% | 23.19 | $ | |
| BP | 1.95% | 34.84 | $ |
Moderna Announces Data to be Presented at the 2025 International Congress of Inborn Errors of Metabolism
CAMBRIDGE, MA / ACCESS Newswire / September 2, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that five abstracts on its investigational mRNA therapeutics have been accepted for presentation at the 2025 International Congress of Inborn Errors of Metabolism (ICIEM), which will be held September 2-6, 2025 in Kyoto, Japan, at the Kyoto International Conference Center. This includes three oral presentations and two poster presentations across the Company's propionic acidemia (PA), methylmalonic acidemia (MMA) and Glycogen Storage Disease Type 1a (GSD1a) programs. This is the first time Moderna will present data at a scientific congress for MMA and GSD1a.
The details of the presentations are as follows:
Oral Presentation #8 - Organic Acidemias: Clinical Burden of Propionic Acidemia in Japan: A real-world evidence cohort study using a hospital-based healthcare database
Time: Wednesday, September 3, 2025, 2:00 - 4:00 PM JST
Order of Presentation: 1
Location: Room 5
Presenter: Yoko Nakajima
Oral Presentation #8 - Organic Acidemias: mRNA-3705 Therapy for Methylmalonic Acidemia: Interim Data from a Phase 1/2 Study
Time: Wednesday, September 3, 2025, 2:00 - 4:00 PM JST
Order of Presentation: 7
Location: Room 5
Presenter: Sabine Fuchs
Oral Presentation #8 - Organic Acidemias: mRNA-3927 for the Treatment of Propionic Acidemia: Final results from mRNA-3927-P101 Part 1 dose-escalation cohorts and cumulative data from ongoing participants
Time: Wednesday, September 3, 2025, 2:00 - 4:00 PM JST
Order of Presentation: 8
Location: Room 5
Presenter: Andreas Schulze
Poster Presentation #P-521: Model-Informed Dose Selection for the Pivotal Study of mRNA-3705 in Methylmalonic Acidemia
Time: Wednesday, September 3, 2025, 6:00 - 7:00 PM JST
Location: Poster 1 - Annex Hall
Presenter: Min Liang
Poster Presentation #P-246: mRNA-3745 Therapy for GSD1a: Interim reported data from Phase 1/2 Ba1ance Study
Time: Thursday, September 4, 2025, 5:30 - 6:30 PM JST
Location: Poster 1 - Annex Hall
Presenter: Nicola Longo
About Moderna
Moderna is a leader in the creation of the field of mRNA medicine. Through the advancement of mRNA technology, Moderna is reimagining how medicines are made and transforming how we treat and prevent disease for everyone. By working at the intersection of science, technology and health for more than a decade, the company has developed medicines at unprecedented speed and efficiency, including one of the earliest and most effective COVID-19 vaccines.
Moderna's mRNA platform has enabled the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases. With a unique culture and a global team driven by the Moderna values and mindsets to responsibly change the future of human health, Moderna strives to deliver the greatest possible impact to people through mRNA medicines. For more information about Moderna, please visit modernatx.com and connect with us on X (formerly Twitter), Facebook, Instagram, YouTube and LinkedIn.
Moderna Contacts
Media:
Chris Ridley
Head of Global Media Relations
+1 617-800-3651
[email protected]
Investors:
Lavina Talukdar
Senior Vice President & Head of Investor Relations
+1 617-209-5834
[email protected]
SOURCE: Moderna, Inc.
View the original press release on ACCESS Newswire
M.Thompson--AMWN